Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 June 2021

Shanghai Cathay Biotech
CHF
388
million
Harmony Biosciences
CHF
121
million
CHF
103
million
Swixx BioPharma
CHF
66
million
bioatla
CHF
62
million
Y-mAbs Therapeutics
CHF
52
million
Neurelis
SpringWorks Therapeutics
CHF
49
million